VTX958 for Crohn's Disease
(Harmony-CD Trial)

Recruiting in Palo Alto (17 mi)

+106 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Ventyx Biosciences, Inc

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial is testing a new medication called VTX958 to help people with moderate to severe Crohn's Disease. The goal is to see if it can reduce inflammation in the intestines and improve symptoms. The study will involve several phases over a period of up to three years.

Eligibility Criteria

This trial is for men and women aged 18-75 with a confirmed diagnosis of Crohn's Disease (CD) that's moderately to severely active. They must have known they had CD for at least 3 months and be able to consent. People can't join if they've tried VTX958 or similar drugs, have other types of colitis, complications from CD requiring surgery, or have a stoma or ileoanal pouch.

Inclusion Criteria

I am between 18 and 75 years old.

I am able to understand and sign the consent form.

I was diagnosed with Crohn's disease over 3 months ago, confirmed by tests and biopsy.

See 1 more

Exclusion Criteria

I have a stoma or an ileoanal pouch.

I have severe complications from Crohn's disease that might need surgery.

I have been diagnosed with a form of colitis.

See 2 more

Treatment Details

Interventions

VTX958 (Other)
VTX958 Placebo (Other)

Trial OverviewThe study tests the effectiveness and safety of VTX958 compared to a placebo in treating Crohn's Disease. Participants are randomly assigned to receive either VTX958 or an inactive substance without knowing which one they're getting, ensuring the results are unbiased.

Participant Groups

3Treatment groups

Experimental Treatment

Placebo Group

Group I: VTX958 Dose BExperimental Treatment1 Intervention

Group II: VTX958 Dose AExperimental Treatment1 Intervention

Group III: VTX958 PlaceboPlacebo Group1 Intervention